The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.
 
Amita Patnaik
Research Funding - Merck
 
Mark A. Socinski
No Relationships to Disclose
 
Matthew A. Gubens
Consulting or Advisory Role - Celgene; Genentech/Roche; Pfizer
Research Funding - Abbvie; Celgene; Genentech/Roche; Merck; Novartis
 
Leena Gandhi
Honoraria - Merck
Consulting or Advisory Role - Genentech/Roche; Merck
Travel, Accommodations, Expenses - Genentech/Roche; Merck
 
James Stevenson
Research Funding - Merck (Inst); Verastem (Inst)
 
Robert D. Bachman
No Relationships to Disclose
 
Jennifer Bourque
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Joy Yang Ge
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Ellie Im
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Shirish M. Gadgeel
No Relationships to Disclose